Home
/
Lineage Cell Therapeutics, Inc.
/
Financials
/
Quarterly
Lineage Cell Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Lineage Cell Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$3.68M
Nov 6, 2025
Q2
2025
Jun 30, 2025
$2.77M
Aug 12, 2025
Q1
2025
Mar 31, 2025
$1.50M
May 13, 2025
Q3
2025
Sep 30, 2024
$3.78M
Nov 6, 2025
Q2
2025
Jun 30, 2024
$1.41M
Aug 12, 2025
Q1
2025
Mar 31, 2024
$1.44M
May 13, 2025
Q3
2024
Sep 30, 2023
$1.25M
Nov 14, 2024
Q2
2024
Jun 30, 2023
$3.23M
Aug 8, 2024
Q1
2024
Mar 31, 2023
$2.39M
May 9, 2024
Q3
2022
Sep 30, 2022
$3.00M
Nov 10, 2022
Q2
2023
Jun 30, 2022
$4.55M
Aug 10, 2023
Q1
2023
Mar 31, 2022
$5.24M
May 11, 2023
Q3
2022
Sep 30, 2021
$2.27M
Nov 10, 2022
Q2
2022
Jun 30, 2021
$512.0K
Aug 11, 2022
Q1
2022
Mar 31, 2021
$391.0K
May 12, 2022
Q3
2021
Sep 30, 2020
$571.0K
Nov 10, 2021
Q2
2021
Jun 30, 2020
$386.0K
Aug 12, 2021
Q3
2018
Sep 30, 2018
$982.0K
Nov 8, 2018
Q2
2018
Jun 30, 2018
$2.55M
Aug 2, 2018
Q3
2018
Sep 30, 2017
$1.69M
Nov 8, 2018
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$3.68M
Nov 6, 2025
Q2
2025
Jun 30, 2025
$2.77M
Aug 12, 2025
Q1
2025
Mar 31, 2025
$1.50M
May 13, 2025
Q3
2025
Sep 30, 2024
$3.78M
Nov 6, 2025
Q2
2025
Jun 30, 2024
$1.41M
Aug 12, 2025
Q1
2025
Mar 31, 2024
$1.44M
May 13, 2025
Q3
2024
Sep 30, 2023
$1.25M
Nov 14, 2024
Q2
2024
Jun 30, 2023
$3.23M
Aug 8, 2024
Q1
2024
Mar 31, 2023
$2.39M
May 9, 2024
Q3
2023
Sep 30, 2022
$3.00M
Nov 9, 2023
Revenue (Net Sales) — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2018
Mar 31, 2018
$701.0K
May 10, 2018
Q3
2017
Sep 30, 2017
$1.69M
Nov 9, 2017
Q2
2017
Jun 30, 2017
$381.0K
Aug 9, 2017
Q1
2018
Mar 31, 2017
$390.0K
May 10, 2018
Q3
2017
Sep 30, 2016
$1.50M
Nov 9, 2017
Q2
2017
Jun 30, 2016
$1.27M
Aug 9, 2017
Q1
2017
Mar 31, 2016
$2.07M
May 10, 2017
Q3
2016
Sep 30, 2015
$2.31M
Nov 4, 2016
Q2
2016
Jun 30, 2015
$2.01M
Aug 9, 2016
Q1
2016
Mar 31, 2015
$1.26M
May 10, 2016
Q3
2015
Sep 30, 2014
$1.19M
Nov 9, 2015
Q2
2015
Jun 30, 2014
$1.11M
Aug 10, 2015
Q1
2015
Mar 31, 2014
$1.07M
May 8, 2015
Q3
2014
Sep 30, 2013
$714.1K
Nov 7, 2014
Q2
2014
Jun 30, 2013
$1.22M
Aug 11, 2014
Q1
2014
Mar 31, 2013
$614.5K
May 12, 2014
Q3
2013
Sep 30, 2012
$1.00M
Nov 12, 2013
Q2
2013
Jun 30, 2012
$1.03M
Aug 9, 2013
Q1
2013
Mar 31, 2012
$652.2K
May 10, 2013
Q3
2011
Sep 30, 2011
$1.14M
Nov 8, 2011
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($29.78M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($30.46M)
Aug 12, 2025
Q1
2025
Mar 31, 2025
($4.14M)
May 13, 2025
Q3
2025
Sep 30, 2024
($3.03M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
($5.76M)
Aug 12, 2025
Q1
2025
Mar 31, 2024
($6.54M)
May 13, 2025
Q3
2024
Sep 30, 2023
($7.11M)
Nov 14, 2024
Q2
2024
Jun 30, 2023
($5.23M)
Aug 8, 2024
Q1
2024
Mar 31, 2023
($4.37M)
May 9, 2024
Q3
2023
Sep 30, 2022
($6.07M)
Nov 9, 2023
Q2
2023
Jun 30, 2022
($6.76M)
Aug 10, 2023
Q1
2023
Mar 31, 2022
($7.09M)
May 11, 2023
Q3
2022
Sep 30, 2021
($7.82M)
Nov 10, 2022
Q2
2022
Jun 30, 2021
($4.79M)
Aug 11, 2022
Q1
2022
Mar 31, 2021
($1.42M)
May 12, 2022
Q3
2021
Sep 30, 2020
($7.76M)
Nov 10, 2021
Q2
2021
Jun 30, 2020
($6.52M)
Aug 12, 2021
Q1
2021
Mar 31, 2020
($8.40M)
May 13, 2021
Q3
2020
Sep 30, 2019
($16.51M)
Nov 4, 2020
Q2
2020
Jun 30, 2019
($30.03M)
Aug 6, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($3.79M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($19.78M)
Aug 12, 2025
Q1
2025
Mar 31, 2025
($6.51M)
May 13, 2025
Q3
2025
Sep 30, 2024
($3.84M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
($5.87M)
Aug 12, 2025
Q1
2025
Mar 31, 2024
($6.66M)
May 13, 2025
Q3
2024
Sep 30, 2023
($6.71M)
Nov 14, 2024
Q2
2024
Jun 30, 2023
($5.02M)
Aug 8, 2024
Q1
2024
Mar 31, 2023
($6.64M)
May 9, 2024
Q3
2023
Sep 30, 2022
($5.25M)
Nov 9, 2023
Q2
2023
Jun 30, 2022
($4.23M)
Aug 10, 2023
Q1
2023
Mar 31, 2022
($6.40M)
May 11, 2023
Q3
2022
Sep 30, 2021
($6.84M)
Nov 10, 2022
Q2
2022
Jun 30, 2021
($7.08M)
Aug 11, 2022
Q1
2022
Mar 31, 2021
($7.05M)
May 12, 2022
Q3
2021
Sep 30, 2020
($6.73M)
Nov 10, 2021
Q2
2021
Jun 30, 2020
($6.40M)
Aug 12, 2021
Q1
2021
Mar 31, 2020
($7.44M)
May 13, 2021
Q3
2020
Sep 30, 2019
($8.42M)
Nov 4, 2020
Q2
2020
Jun 30, 2019
($10.82M)
Aug 6, 2020